Sorafenib
- 1 January 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 68 (2), 251-258
- https://doi.org/10.2165/00003495-200868020-00007
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- SorafenibDrugs, 2007
- Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5Cancer Research, 2006
- Discovery and development of sorafenib: a multikinase inhibitor for treating cancerNature Reviews Drug Discovery, 2006
- Phase II Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaJournal of Clinical Oncology, 2006
- Emerging drugs for hepatocellular carcinomaEmerging Drugs, 2006
- Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutantBlood, 2006
- Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumorsAnnals Of Oncology, 2006
- Sorafenib (BAY 43‐9006, Nexavar®), a Dual‐Action Inhibitor That Targets RAF/MEK/ERK Pathway in Tumor Cells and Tyrosine Kinases VEGFR/PDGFR in Tumor VasculatureMethods in enzymology, 2006
- Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokineticsCancer Chemotherapy and Pharmacology, 2005
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004